文献速递类风湿关节炎系统性红斑狼疮其他结缔组织病

羟氯喹长期使用与风湿病患者SARS-CoV-2感染风险的关系

Long-term hydroxychloroquine use in patients with rheumatic conditions and development of SARS-CoV-2 infection: a retrospective cohort study.
PubMed 文献 · Lancet Rheumatol · 2020-09-21

该回顾性队列研究基于美国退伍军人健康管理系统数据,纳入2020年3月1日至6月30日期间患有类风湿关节炎、系统性红斑狼疮或相关风湿病的退伍军人,比较接受长期羟氯喹治疗者与倾向评分匹配的未接受者。

要点

  • 感染相关住院、ICU需求及死亡等次要结局在两组间无显著差异。

核心结论

  • 在风湿病患者中,长期羟氯喹使用与SARS-CoV-2感染风险降低无关。

研究设计与样本

  • 回顾性队列研究,基于美国退伍军人健康管理数据库,纳入2020年3月1日存活、年龄≥18岁、按ICD-10诊断编码患有类风湿关节炎、系统性红斑狼疮或相关风湿病的退伍军人。
  • 为每位患者计算倾向评分,每位接受羟氯喹者匹配2名未接受者作为对照。
  • 主要终点为2020年3月1日至6月30日PCR确诊SARS-CoV-2感染比例。

主要发现

  • 感染者的次要结局(住院、ICU、死亡)两组无显著差异。

临床怎么用

  • 不建议以预防SARS-CoV-2感染为目的为风湿病患者处方或维持羟氯喹。
  • 风湿病患者羟氯喹的原有治疗指征应依据其风湿病病情独立评估。

局限性

  • 为回顾性队列研究,可能存在残余混杂。
  • 研究对象为美国退伍军人群体,外推至其他人群需谨慎。
  • 研究期间为2020年3月1日至6月30日,结果受当时检测策略与流行特征影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hydroxychloroquine is one of several agents being evaluated in the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. We aimed to examine whether patients with rheumatological conditions receiving chronic hydroxychloroquine therapy are at less risk of developing SARS-CoV-2 infection than those not receiving hydroxychloroquine. METHODS: This retrospective cohort study included de-identified information of all veterans in the US Veterans Health Administration clinical administrative database aged 18 years or older with rheumatoid arthritis, systemic lupus erythematosus, or associated rheumatological conditions (based on International Classification of Diseases, 10th edition, diagnostic codes) who were alive on March 1, 2020. A propensity score was calculated for each patient, and each patient who was receiving hydroxychloroquine was matched to two patients who were not receiving hydroxychloroquine (controls). The primary endpoint was the proportion of patients with PCR-confirmed SARS-CoV-2 infection among those receiving chronic hydroxychloroquine versus the propensity-matched patients not receiving chronic hydroxychloroquine between March 1 and June 30, 2020. Secondary outcomes were hospital admission associated with SARS-CoV-2 infection; intensive care requirement associated with SARS-CoV-2 infection; mortality associated with SARS-CoV-2 infection; and overall rates of any hospital admission and mortality (ie, all cause). Multivariate logistic regression analysis was done to determine independent variables for the development of active SARS-CoV-2 infection. FINDINGS: Between March 1 and June 30, 2020, 10 703 patients receiving hydroxychloroquine and 21 406 patients not receiving hydroxychloroquine were included in the primary analysis. The incidence of active SARS-CoV-2 infections during the study period did not differ between patients receiving hydroxychloroquine and patients not receiving hydroxychloroquine (31 [0·3%] of 10 703 vs 78 [0·4%] of 21 406; odds ratio 0·79, 95% CI 0·52-1·20, p=0·27). There were no significant differences in secondary outcomes between the two groups in patients who developed active SARS-CoV-2 infection. For all patients in the study, overall mortality was lower in the hydroxychloroquine group than in the group of patients who did not receive hydroxychloroquine (odds ratio 0·70, 95% CI 0·55-0·89, p=0·0031). In multivariate logistic regression analysis, receipt of hydroxychloroquine was not associated with the development of active SARS-CoV-2 infection (odds ratio 0·79, 95% CI 0·51-1·42). INTERPRETATION: Hydroxychloroquine was not associated with a preventive effect against SARS-CoV-2 infection in a large group of patients with rheumatological conditions. FUNDING: None.

来源:Lancet Rheumatol,查看原文。版权归原作者所有。

引用

  1. Gentry CA, Humphrey MB, Thind SK, et al. Long-term hydroxychloroquine use in patients with rheumatic conditions and development of SARS-CoV-2 infection: a retrospective cohort study. Lancet Rheumatol. 2020. PMID: 32984847. doi:10.1016/S2665-9913(20)30305-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。